How to Write a Business Plan
Turn your Project into an Investment Magnet – £300 (we are in Beta) free E-course
Pharmaceutical and Biotechnology projects need a business plan if they are going to raise finance, and that is just what we are here to help you achieve. We are going to assist you in putting together a business plan that will ensure that your healthcare technology project gets the funding it needs. We will turn your project into an investment magnet. Good business plans raise money and you are going to be very please you took our advice, sign up now for our course.
Over the years IDA consultants have worked with a large number of companies to undertake the planning process and provide the contents they need for their business plan, and 100% of our clients obtained the funding they needed to take them to the next step.
£300 (we are in Beta Free) E-course on How to Write a Business Plan
Our £300 (we are in Beta) Free E-course on how to write a business plan will take you through an 11 step programme and provides an outline of the sections of the business plan, guidance on the kind of information that is needed and useful resource and document templates. Fill in the Form to Join and Turn Your Business into an Investor Magnet.
Sign up for £300 Free (we are in Beta)
We don’t like spam, we will not share your data and we will guard it like you would.
Course Content
- Session 1 – Situation Review; before you can decide where your going, its important to understand where you are now.
- Session 2 – Indication Review; what is your target indication? what other opportunities are there? its all about adding value.
- Session 3 – Intellectual Property; this is where your value lies, its critical to protect and optimize it, its not just about patents.
- Session 4 – Regulatory Strategy; the regulations are the gatekeepers to the market and the correct strategy can be the difference between success and failure. You will be a success.
- Session 5 – Markets; its not market sizes its market dynamics, investors know this, do you?
- Session 6 – Indication Selection; make sure your going for the correct markets to optimize your goals and strategies.
- Session 7 – Development planning; how are you going to develop this product? quickly and cost effectively? its risk management.
- Session 8 – Manufacturing and GMP; knowing how the requirements will impact on your business is critical to cash flow and strategy.
- Session 9 – Regulatory Advice, get your plans rubber stamped, it adds masses of credibility, a real investor magnet.
- Session 10 – Cost and Financial Planning; you know what your going to do, but just how much is it going to cost?
- Session 11 – The Business Plan; bringing it all together to attract the investment.
The Book
This course is extracted from the definitive book on How to Write a Business Plan for Health Technology Companies. We will make this book avaialble to you shortley, its just undergoing its final edit and will soon be printed.
Take advantage of our 100% fundraising record when writing your business plan.
Pingback: Drug Regulators, FDA CDER, Publish Guidance on Q4B Annex 8 Sterility Test General Chapter for ICH Regions | Drug Development Consultant and Regulatory Consultant
Pingback: Drug Regulators, FDA, Publish Guidance on An Acceptable Circular of Information for the Use of Human Blood and Blood Components | Drug Development Consultant and Regulatory Consultant
Pingback: Drug Regulators, FDA, Publish Guidance for Industry on New Contrast Imaging Indication Considerations for Devices and Approved Drug and Biological Products. | Drug Development Consultant and Regulatory Consultant
Pingback: Drug Regulatory Guidance, Planning for the Effects of High Absenteeism to Ensure Availability of Medically Necessary Drug Products. | Drug Development Consultant and Regulatory Consultant
Pingback: Drug Regulators, EMEA, Publish Questions and Answers on Gene Therapy | Drug Development Consultant and Regulatory Consultant
Pingback: Drug Regulators, European Medicines Agency, Publish Concept Paper on Revision of the Notes for Guidance on Gene Transfer Medicinal Products | Drug Development Consultant and Regulatory Consultant
Pingback: Drug Regulators, EMEA, Publish Guidance on the Evaluation of Drugs for the Treatment of Gastroesophageal Reflux Disease | Drug Development Consultant and Regulatory Consultant
Pingback: Device Regulators, MHRA, Publish Poster on Mattress Decontamination | Drug Development Consultant and Regulatory Consultant
Pingback: £70 million Boost for UK manufacturing (including Regenerative medicines) | Drug Development Consultant and Regulatory Consultant
Pingback: Drug Regulators, EMEA, Publish Guidance on Herbal Medicinal Products, Test Materials for Genotoxicity | Drug Development Consultant and Regulatory Consultant
Pingback: Regulators Publish Guidance for Industry, Non Clinical Safety Studies for the Conduct of Human Clinical Trials and Marketing Authorization. | Drug Development Consultant and Regulatory Consultant
Pingback: Dedication Recognised – IDA wins award for mentor work | Drug Development Consultant and Regulatory Consultant
Pingback: Drug Regulators, EMEA, Publish Draft Concept Paper on the Risk Based Approach for Advanced Therapy Medical Products | Drug Development Consultant and Regulatory Consultant
Pingback: Drug Regulators EMEA, Publish Guidance on Clinical Investigations of Medicinal Products Intended for the Treatment of Glucocorticoid-Induced Osteoporosis | Drug Development Consultant and Regulatory Consultant
Pingback: Drug Regulators, EMEA, Publish Guideline on Investigations of Medicinal Products in the Treatment of Epileptic Disorders | Drug Development Consultant and Regulatory Consultant
Pingback: Drug Regulators, EMEA, Release Overview of Comments Received on Draft Guidance on Clinical Evaluation of Diagnostic Agents. | Drug Development Consultant and Regulatory Consultant
Pingback: Drug Regulators, FDA - CDER, Publish Guidance on Use of Mechanical Calibration of Dissolution Apparatus CGMP | Drug Development Consultant and Regulatory Consultant
Pingback: Drug Regulators, FDA- CDER, Publish Guidance on the Assessment of Abuse Potential of Drugs. | Drug Development Consultant and Regulatory Consultant
Pingback: Drug Regulators, EMA, Publish Overview of Comments Received on Reflection Paper, Ethanol Content in Herbal Medicinal Products | Drug Development Consultant and Regulatory Consultant
Pingback: Drug Regulators, EMA, Publish Reflection Paper on Ethanol Content in Herbal Medicinal Products and Tranditional Herbal Medicinal Products Used in Children | Drug Development Consultant and Regulatory Consultant
Pingback: Drug Regulators EMEA, Publish Overview of Comments Received on Selection of Test Materials for Genotoxicity Testing For Traditional Herbal Medicinal Products | Drug Development Consultant and Regulatory Consultant
Pingback: Drug Regulators, MHRA, Publish Consultation, Intention to Amend the Medicines for Human Use Regulations 2008 (SI2008/1692) | Drug Development Consultant and Regulatory Consultant
Pingback: Drug Regulators, MHRA, Publish Consultation Letter MLX 364, The Regulation of Nicotine Containing Products. | Drug Development Consultant and Regulatory Consultant
Pingback: Drug Regulators, EMEA, Publish Concept Paper on Need to Revise Points to Consider on the Clinical Investigation of Medicinal Products Other than NSAIDs in Rheumatoid Arthritis | Drug Development Consultant and Regulatory Consultant
Pingback: Drug Regulators, EMEA, Publish an Overview of Comments Received on Draft Guidance on Clinical Investigations of Medicinal Products Used in Osteoarthritis | Drug Development Consultant and Regulatory Consultant
Pingback: Drug Regulators, EMEA, Publish Addendum to the Note for Guidance on Evaluation of Medicinal Products Indicated for the Treatment of Bacterial Infections | Drug Development Consultant and Regulatory Consultant
Pingback: Drug Regulators, FDA, Publish Guidance For Industry on Content of a Complete Submission for the Evaluation of Proprietary Names. | Drug Development Consultant and Regulatory Consultant
Pingback: regulators EMEA (EMA), Publish a Concept Paper on the Need For Guidance on Clinical Investigations of Medicinal Products in the Treatment of Diabetes Mellitus | Drug Development Consultant and Regulatory Consultant
Pingback: Drug Regulators, EMA (EMEA), Publish draft guidance on Clinical Investigations in the Treatment of Diabetes Mellitus | Drug Development Consultant and Regulatory Consultant
Pingback: Drug Regulators, MHRA, Publish Consultation Document on ARM 65 Algopain-EZE 140MG Medicated Plaster, Request to Reclassify a Prodcut from POM to P | Drug Development Consultant and Regulatory Consultant
Pingback: Drug Regulators, EMEA (EMA), Publish Draft Guidance on the Investigation of Bioequivalence. | Drug Development Consultant and Regulatory Consultant
Pingback: Drug Regulators, FDA, Publish Draft Guidance for Industry, Non-Inferiority Clinical Trials | Drug Development Consultant and Regulatory Consultant
Pingback: Drug Regulators, FDA, Publish Draft Guidance on Adaptive Design Clinical Trials for Drugs and Biologicals. | Drug Development Consultant and Regulatory Consultant
Pingback: Device Regulators, MHRA, Publish Draft for Comment on Vigilance Systems for CE-Marked Medical Devices - Cardiac Ablation Catheters. | Drug Development Consultant and Regulatory Consultant